GLIOSARCOMA
Clinical trials for GLIOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new GLIOSARCOMA trials appear
Sign up with your email to follow new studies for GLIOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hormone therapy explored for aggressive brain tumor
Disease control TerminatedThis early-phase study tested whether natural progesterone, a hormone normally involved in pregnancy, could help control recurrent glioblastoma (a fast-growing brain cancer). Four adults whose cancer had returned after standard treatments received daily progesterone injections un…
Matched conditions: GLIOSARCOMA
Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental brain tumor combo shows promise but trial halted early
Disease control TerminatedThis study tested a new drug called zotiraciclib (TG02) combined with the standard chemotherapy temozolomide in adults with recurrent anaplastic astrocytoma or glioblastoma. The goal was to find the safest dose and see if the combination worked better than temozolomide alone. The…
Matched conditions: GLIOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental drug navtemadlin tested for glioblastoma
Disease control TerminatedThis early-phase trial tested the drug navtemadlin in 32 adults with glioblastoma, a type of brain cancer. The study aimed to find the best dose and check side effects, both for newly diagnosed and recurrent cases. The trial was terminated early, so results are limited.
Matched conditions: GLIOSARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Brain cancer drug trial halted after just two patients
Disease control TerminatedThis study tested a new drug called VAL-083 in people with glioblastoma, an aggressive brain cancer that had returned after standard treatments. The trial aimed to see if VAL-083 could help patients live longer. However, the study was stopped early after only 2 people enrolled, s…
Matched conditions: GLIOSARCOMA
Phase: PHASE3 • Sponsor: DelMar Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:46 UTC